Metabolic reprogramming drives acquired venetoclax resistance in Acute Myeloid Leukemia and reveals targetable vulnerabilities (2025)
- Authors:
- USP affiliated authors: CÂMARA, NIELS OLSEN SARAIVA - ICB ; LOTUFO, LETICIA VERAS COSTA - ICB ; REGO, EDUARDO MAGALHÃES - FM ; MACHADO NETO, JOÃO AGOSTINHO - ICB ; LIMA, KELI CRISTINA DE - FM ; QUEIROZ, GUSTAVO NERY DE - ICB ; CIPELLI, MARCELLA - ICB
- Unidades: ICB; FM
- DOI: 10.1182/blood-2025-6785
- Subjects: FARMCACOLOGIA; IMUNOLOGIA; LEUCEMIA MIELOIDE AGUDA; ANTINEOPLÁSICOS; FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO; PROTEÔMICA; APOPTOSE; EXPRESSÃO GÊNICA; MUTAÇÃO GENÉTICA
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Publisher place: Washington
- Date published: 2025
- Source:
- Conference titles: ASH Annual Meeting and Exposition
- Status:
- Artigo possui acesso gratuito no site do editor (Bronze Open Access)
- Versão do Documento:
- Versão publicada (Published version)
- Acessar versão aberta:
-
ABNT
LIMA, Keli et al. Metabolic reprogramming drives acquired venetoclax resistance in Acute Myeloid Leukemia and reveals targetable vulnerabilities. Blood. Washington: Instituto de Ciências Biomédicas, Universidade de São Paulo. Disponível em: https://doi.org/10.1182/blood-2025-6785. Acesso em: 06 maio 2026. , 2025 -
APA
Lima, K., Queiroz, G. N. de, Cipelli, M., Tomaz, V., Cortes, L. G. F., Silva, M. B., et al. (2025). Metabolic reprogramming drives acquired venetoclax resistance in Acute Myeloid Leukemia and reveals targetable vulnerabilities. Blood. Washington: Instituto de Ciências Biomédicas, Universidade de São Paulo. doi:10.1182/blood-2025-6785 -
NLM
Lima K, Queiroz GN de, Cipelli M, Tomaz V, Cortes LGF, Silva MB, Guedes R, Campregher PV, Câmara NOS, Costa-Lotufo LV, Rego EM, Machado Neto JA. Metabolic reprogramming drives acquired venetoclax resistance in Acute Myeloid Leukemia and reveals targetable vulnerabilities [Internet]. Blood. 2025 ; 146 6785.[citado 2026 maio 06 ] Available from: https://doi.org/10.1182/blood-2025-6785 -
Vancouver
Lima K, Queiroz GN de, Cipelli M, Tomaz V, Cortes LGF, Silva MB, Guedes R, Campregher PV, Câmara NOS, Costa-Lotufo LV, Rego EM, Machado Neto JA. Metabolic reprogramming drives acquired venetoclax resistance in Acute Myeloid Leukemia and reveals targetable vulnerabilities [Internet]. Blood. 2025 ; 146 6785.[citado 2026 maio 06 ] Available from: https://doi.org/10.1182/blood-2025-6785 - Metabolic reprogramming represents a targetable mechanism to overcome acquired resistance to venetoclax in acute myeloid leukemia
- Overcoming acquired venetoclax resistance in acute myeloid leukemia through cell metabolism targeting
- NT157 exhibits antineoplastic effects by targeting IRS and STAT3/5 signaling in multiple myeloma
- Gut microbiota resilience mechanisms against pthogen infection and its role in infammatory Bowel Disease
- Cellular and molecular effects of Eribulin in preclinical models of hematologic neoplasms
- Synthesis and evaluation of 2-substituted quinazolin-4(3H)-ones as potential antileukemic agents
- In Silico, in vitro, and in vivo studies of a 2-substituted quinazolin-4(3H)-one in T-cell acute lymphoblastic leukemia
- Chromomycin A2 exhibits antileukemic effects by coordinated disruption of survival pathways
- All-trans retinoic acid potentiates cell death induced by quizartinib in acute myeloid leukemia with FLT3-ITD mutations
- Translational investigation of tolinapant (ASTX660) in acute myeloid leukemia by integrating clinical, bioinformatic and pharmacological approaches
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Por se tratar de integração com serviço externo, podem existir diferentes versões do trabalho (como preprints ou postprints), que podem diferir da versão publicada.
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
